Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business

PHILADELPHIA, May 31, 2019 -- (Healthcare Sales & Marketing Network) -- Iovance Biotherapeutics, a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, has expanded its relations... Biopharmaceuticals, Oncology Iovance Biotherapeutics, WuXi ATU, tumor-infiltrating lymphocyte, lifileucel
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news